Oseltamivir dosing for influenza infection in premature neonates. - Wikidata - awgldk - TriplyDB

Oseltamivir dosing for influenza infection in premature neonates.

Oseltamivir dosing for influenza infection in premature neonates.

http://www.wikidata.org/entity/Q33996464

about

Innovative clinical trial design for pediatric therapeutics Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013 High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir.Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit Pharmacokinetic studies in infants using minimal-risk study designs Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.Determination of appropriate dosing of influenza drugs in pediatric patients.The use of antiviral drugs for influenza: Guidance for practitioners, 2012/2013; Paediatric summary Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak.Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.Prematurity and the burden of influenza and respiratory syncytial virus disease.Oseltamivir for influenza infection in children: risks and benefits.Oseltamivir dosing in premature infants.The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.Oseltamivir treatment for influenza does not increase digestive intolerance in preterm infants.Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.L’utilisation d’antiviraux contre l’influenza : des conseils pour les praticiens en 2012–2013 – Sommaire relatif à la pédiatrie.Viral Respiratory Infections in the Neonatal Intensive Care Unit-A Review

P2860

Q24635308-FD792092-5989-4F59-9537-0178105DB28D Q30409023-B4AF68E3-E953-4C1A-98A1-7C9018C23634 Q34389114-A3BDC6FA-2438-41FA-B49E-42CF07534E43 Q34483638-4EB7A198-A0CB-4501-BE78-A927E7A2067E Q34743315-A1E1C4E9-34A3-4977-9653-D354F7CB9E85 Q36086446-6BBB6DC2-2305-478F-887F-93A9B8E1B2BD Q36438116-E242031D-E8F4-484C-AD8E-51AFEF86C70E Q36584645-15F743BF-7114-45F0-A226-DFD1757B3624 Q36630178-704D4C75-C51A-48AB-B521-ADCB989C13DD Q36922941-D2FFAA22-4077-4AC6-8BAE-E01EAFBB7405 Q37259653-5D5EBBDC-D082-4482-BBCD-AFA60E72A842 Q37828363-8EC09956-8C9B-448B-9590-B73798DFF887 Q38051213-25F3C04F-EFAF-4B27-A6DE-3C4EF9999F09 Q38084212-8BAF5B5D-6FF1-44D6-8150-2B506A82F6D4 Q38637989-C5D99110-5D1E-4000-91D1-F1549559CF4E Q38652336-E9D2517A-0676-4935-AE35-EBF61A08E43F Q41890159-3B8494BB-9EA8-4437-B574-54F451653F16 Q42216493-DE8D2D96-E8DC-46ED-8794-3F7C3DECC964 Q42246526-9C69D818-0D6A-4F12-9275-6089BEEE101C Q43663687-BA9112CC-B823-41D4-9426-CF393C857E77 Q46499031-43975D51-12CE-4DFA-B651-CAF56859F8DF Q58587564-48A67FDC-CF6A-40FA-923F-3D10A8E8F159

P2860

Oseltamivir dosing for influenza infection in premature neonates.

http://www.wikidata.org/entity/Q33996464

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Oseltamivir dosing for influenza infection in premature neonates.

@ast

Oseltamivir dosing for influenza infection in premature neonates.

@en

type

label

Oseltamivir dosing for influenza infection in premature neonates.

@ast

Oseltamivir dosing for influenza infection in premature neonates.

@en

prefLabel

Oseltamivir dosing for influenza infection in premature neonates.

@ast

Oseltamivir dosing for influenza infection in premature neonates.

@en

P1433

Q33996464-6896D24F-FDD8-4D13-982C-A657BD0F721C

P1476

Q33996464-E91E454D-4B4C-4060-9C43-4459F877EE7A

P2093

Q33996464-272F829D-CF93-46C6-9229-DB8D22A80E42

Q33996464-424DA7DD-CA35-4139-A689-5EBCF4CCB408

Q33996464-5F151F04-177D-4FD6-BC62-6D96BFE9FA81

Q33996464-839E1D7C-B70D-46D4-9754-CC33DEA1A0D0

Q33996464-8EF391B3-9161-494B-B434-61DE92377AD8

Q33996464-B369A7B9-9347-485D-B6FE-3A37290FB5F8

Q33996464-B49046F1-3728-49F2-9A27-372F14E4DF5C

Q33996464-EE0C077F-D5A7-4392-B6DB-689650512A29

P2860

Q33996464-37D812EA-7501-478C-8A1E-C7AD7C4CCDC4

Q33996464-525FDBCD-D7C5-4549-AA2D-DF499554BF3B

Q33996464-CF717A75-CB89-470B-B1C1-8CBDFFCB3478

Q33996464-E592498C-8772-478E-94A2-742E01E5CA5F

P304

Q33996464-6992A96E-640B-429A-BE78-45691C179FCE

P31

Q33996464-93CEF08A-C46B-4BDE-8318-ABFD6A3A4692

P356

Q33996464-14CDA664-A213-41E8-9874-F1F93FC74FB0

P407

Q33996464-AB7D5867-ABDD-4198-9930-35D52A04775A

P433

Q33996464-E80CBC3B-F674-4205-BA72-CAC923166737

P478

Q33996464-3E9B27DB-FD63-4F8C-955B-FA27847D2A1E

P577

Q33996464-D8BFC823-1062-4D6F-A98E-CBBFA94D36FC

P5875

Q33996464-4520BF8C-AB49-4D83-9691-237B62660921

P698

Q33996464-9718BE70-563D-44F1-9EC0-A9EBC6F4C563

P932

Q33996464-94818ADB-9AC7-4731-B466-7B14F12B2FF5

P356

P1433

The Journal of Infectious Diseases

P1476

Oseltamivir dosing for influenza infection in premature neonates.

@en

P2093

David W Kimberlin

http://www.w3.org/2001/XMLSchema#string

Edward P Acosta

http://www.w3.org/2001/XMLSchema#string

John Wimmer

http://www.w3.org/2001/XMLSchema#string

Joni Wade

http://www.w3.org/2001/XMLSchema#string

National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

http://www.w3.org/2001/XMLSchema#string

Penelope Jester

http://www.w3.org/2001/XMLSchema#string

Peter Gal

http://www.w3.org/2001/XMLSchema#string

Richard J Whitley

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Developmental pharmacology--drug disposition, action, and therapy in infants and children.

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.

P304

563-566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/654930

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

202

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44900763

http://www.w3.org/2001/XMLSchema#string

P698

20594104

http://www.w3.org/2001/XMLSchema#string

P932

2904429

http://www.w3.org/2001/XMLSchema#string